Please assess the completion status of the following clinical trial:

Trial Title: ROSA® Hip System THA PMCF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion:~1. Age 18 - 80 years~2. Body mass index ≤40 (BMI = kg/m2)~3. Patient is willing and able to provide informed consent~4. Patient qualifies for primary THA, via an anterior approach, due to osteoarthritis or avascular necrosis of the hip based on Investigator's clinical judgment~5. Independent of study participation, patient is a candidate and meets the indications and none of the contraindications for use with the ROSA Hip System~Exclusion:~1. Has undergone an orthopaedic procedure of the spine or lower extremity, or is currently participating in a pain management clinical study of any joint, within the last 6 months or planned within the next 6 months~2. Patients receiving simultaneous bilateral hip arthroplasties are excluded from participation in this study; as well as any participants with staged bilateral arthroplasties within 6 months of each other~3. Active infection, sepsis, osteomyelitis~4. Patient is at a high risk for dislocation including those with long-segment spinal fusions (\>3 levels) and neuromuscular disorders~5. Inflammatory (rheumatoid or psoriatic arthritis) or post-traumatic arthropathy, or any other degenerative joint disease not consistent with osteoarthritis~6. Would, in the Investigator's opinion, be unwilling or unable to comply with the postoperative follow-up schedule~7. Patient is considered a member of a vulnerable population (pregnant, prisoner, mentally incompetent, etc.)~8. Previous hardware in the proximal femur or acetabulum from a prior orthopaedic procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Robotic-Assisted THA (Type: EXPERIMENTAL): Consecutive participants will receive THA via the ROSA Hip System.

Based on this trial design, predict the completion outcome and termination type (if applicable).